Evidence map›Paper›PMID 35680931›Full record

ArticleScientific reports2022

Elevated plasma level of the glycolysis byproduct methylglyoxal on admission is an independent biomarker of mortality in ICU COVID-19 patients.

Fadhel A Alomar, Marai N Alshakhs, Salah Abohelaika, Hassan M Almarzouk, Mohammed Almualim, Amein K Al-Ali, Fahad Al-Muhanna, Mohammed F Alomar, Mousa J Alhaddad, Mohammed S Almulaify and 12 more

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Fadhel A Alomar *Department of Pharmacology and Toxicology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, P. O. Box 1982, Dammam, 31441, Saudi Arabia. falomar@iau.edu.sa.
Marai N Alshakhs *Department of Internal Medicine, Dammam Medical Complex, Dammam, Saudi Arabia.
Salah Abohelaika *Clinical Pharmacology Department, Qatif Central Hospital, Ministry of Health, Qatif, Saudi Arabia.
Hassan M AlmarzoukDepartment of Internal Medicine, Dammam Medical Complex, Dammam, Saudi Arabia.
Mohammed AlmualimIntenstive Care Unit, Qatif Central Hospital, Ministry of Health, Qatif, Saudi Arabia.
Amein K Al-AliCollege of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Fahad Al-MuhannaCollege of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Mohammed F AlomarCollege of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Mousa J AlhaddadDepartment of Internal Medicine, Dammam Medical Complex, Dammam, Saudi Arabia.
Mohammed S AlmulaifyDepartment of Internal Medicine, Dammam Medical Complex, Dammam, Saudi Arabia.
Faisal S AlessaDepartment of Internal Medicine, Dammam Medical Complex, Dammam, Saudi Arabia.
Ahmed S AlsalmanDepartment of Internal Medicine, Dammam Medical Complex, Dammam, Saudi Arabia.
Ahmed AlaswadClinical Pharmacology Department, Qatif Central Hospital, Ministry of Health, Qatif, Saudi Arabia.
Sean R BidaseeDepartments of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.
Hassan A AlsaadDepartment of Pharmacology and Toxicology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, P. O. Box 1982, Dammam, 31441, Saudi Arabia.
Rudaynah A AlaliCollege of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Mona H AlSheikhCollege of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Mohammed S AkhtarCollege of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Mohammed Al MohainiBasic Sciences Department, College of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Al Ahsa, 31982, Saudi Arabia.
Abdulkhaliq J AlsalmanDepartment of Clinical Pharmacy, Faculty of Pharmacy, Northern Border University, Rafha, Saudi Arabia.
Hussain AlturaifiKing Fahad Hospital Hofuf, Alahsa, Saudi Arabia.
Keshore R BidaseeDepartments of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA. kbidasee@unmc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biomarkers to identify ICU COVID-19 patients at high risk for mortality are urgently needed for therapeutic care and management. Here we found plasma levels of the glycolysis byproduct methylglyoxal (MG) were 4.4-fold higher in ICU patients upon admission that later died (n = 33), and 1.7-fold higher in ICU patients that survived (n = 32),compared to uninfected controls (n = 30). The increased MG in patients that died correlated inversely with the levels of the MG-degrading enzyme glyoxalase-1 (r

Indexed as

COVID-19Intensive Care UnitsBiomarkersGlycolysisHumansPyruvaldehydeBiomarkersPyruvaldehyde

Identifiers

PMID35680931
PMCPMC9178541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.